Evidence map›Paper›PMID 34271294›Full record

ArticleJournal of critical care2021

Mortality associated with early changes in ARDS severity in COVID-19 patients - Insights from the PRoVENT-COVID study.

Michiel T U Schuijt, Ignacio Martin-Loeches, Marcus J Schultz, Frederique Paulus, Ary Serpa Neto, PRoVENT-COVID, PRoVENT-COVID Collaborative Group members. Electronic address: provent-covid@amsterdamumc.nl, PRoVENT-COVID Collaborative Group members

Open access · hybridAbstract read
In one paragraph

Article in Journal of critical care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. RT education and COVID-19 pneumonia discharge quality.Canadian journal of respiratory therapy : CJRT = Revue canadienne de la therapie respiratoire : RCTR · 2023
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 5 countries.

Michiel T U SchuijtDepartment of Intensive Care, Amsterdam UMC, location AMC, Amsterdam, the Netherlands. Electronic address: m.t.u.schuijt@amsterdamumc.nl.
Ignacio Martin-LoechesDepartment of Clinical Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St James's Hospital & Trinity Centre for Health Sciences, Dublin, Ireland.
Marcus J SchultzDepartment of Intensive Care, Amsterdam UMC, location AMC, Amsterdam, the Netherlands; Mahidol Oxford Tropical Medicine Research Unit (MORU), Mahidol University, Bangkok, Thailand; Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Frederique PaulusDepartment of Intensive Care, Amsterdam UMC, location AMC, Amsterdam, the Netherlands; ACHIEVE, Centre of Applied Research, Amsterdam University of Applied Sciences, Faculty of Health, Amsterdam, the Netherlands.
Ary Serpa NetoDepartment of Intensive Care, Amsterdam UMC, location AMC, Amsterdam, the Netherlands; Department of Critical Care Medicine, Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), Monash University, Melbourne, Australia.
PRoVENT-COVID
PRoVENT-COVID Collaborative Group members. Electronic address: provent-covid@amsterdamumc.nl
PRoVENT-COVID Collaborative Group members
Amsterdam University Medical Centers · NLMonash University · AUAustralian and New Zealand Intensive Care Society · AUSt. James's Hospital · IEMahidol University · THMahidol Oxford Tropical Medicine Research Unit · THUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe investigated changes in ARDS severity and associations with outcome in COVID-19 ARDS patients.

methodsWe compared outcomes in patients with ARDS classified as 'mild', 'moderate' or 'severe' at calendar day 1, and after reclassification at calendar day 2. The primary endpoint was 28-day mortality. We also identified which ventilatory parameters had an association with presence of severe ARDS at day 2. We repeated the analysis for reclassification at calendar day 4.

resultsOf 895 patients, 8.5%, 60.1% and 31.4% had mild, moderate and severe ARDS at day 1. These proportions were 13.5%, 72.6% and 13.9% at day 2. 28-day mortality was 25.3%, 31.3% and 32.0% in patients with mild, moderate and severe ARDS at day 1 (p = 0.537), compared to 28.6%, 29.2% and 44.3% in patients reclassified at day 2 (p = 0.005). No ventilatory parameter had an independent association with presence of severe ARDS at day 2. Findings were not different reclassifying at day 4.

conclusionsIn this cohort of COVID-19 patients, ARDS severity and mortality between severity classes changed substantially over the first 4 days of ventilation. These findings are important, as reclassification could help identify target patients that may benefit from alternative approaches.

Indexed as

COVID-19Respiratory Distress SyndromeHumansLungRespiration, ArtificialSARS-CoV-2Acute respiratory distress syndromeARDSCoronavirus disease 2019COVID–19Mortality

Identifiers

PMID34271294
PMCPMC8260578
OpenAlexW3179969245

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.